1. Home
  2. ABSI vs ESPR Comparison

ABSI vs ESPR Comparison

Compare ABSI & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Absci Corporation

ABSI

Absci Corporation

HOLD

Current Price

$3.04

Market Cap

357.9M

Sector

Health Care

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$2.61

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABSI
ESPR
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
357.9M
731.9M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
ABSI
ESPR
Price
$3.04
$2.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$7.47
$7.60
AVG Volume (30 Days)
4.0M
5.2M
Earning Date
05-12-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
10.64
60.71
EPS
N/A
N/A
Revenue
$4,534,000.00
$403,135,000.00
Revenue This Year
$631.04
$2.92
Revenue Next Year
$75.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.31
52 Week Low
$2.01
$0.73
52 Week High
$5.23
$4.18

Technical Indicators

Market Signals
Indicator
ABSI
ESPR
Relative Strength Index (RSI) 56.60 43.81
Support Level $2.45 $2.37
Resistance Level $3.26 $3.02
Average True Range (ATR) 0.25 0.19
MACD 0.03 0.03
Stochastic Oscillator 74.43 47.02

Price Performance

Historical Comparison
ABSI
ESPR

About ABSI Absci Corporation

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: